Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cgh.2015.02.024PMID 25724701PMCID PMC4653068
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland.

  2013cited by this paper
• Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review

  2013cited by this paper
• Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

  2013cited by this paper
• A Paper-Based Multiplexed Transaminase Test for Low-Cost, Point-of-Care Liver Function Testing

  2012cited by this paper
• Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.

  2010cited by this paper
• Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.

  2010cited by this paper
• Outcome of liver transplantation for drug‐induced acute liver failure in the United States: Analysis of the united network for organ sharing database

  2009cited by this paper
• Drug-Induced Liver Injury Network (DILIN) Prospective Study

  2009cited by this paper
• American Thoracic Society Documents An Official ATS Statement : Hepatotoxicity of Antituberculosis Therapy

  2006cited by this paper
• The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.

  2006cited by this paper
• The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.

  2006cited by this paper
• Isoniazid for latent tuberculosis infection: approaching 40 and reaching its prime.

  2003cited by this paper
• Use of isoniazid for latent tuberculosis infection in a public health clinic.

  2003cited by this paper
• Biological and chemical terrorism: strategic plan for preparedness and response.

  2000cited by this paper
• Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.

  2000cited by this paper
• Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.

  1999cited by this paper
• Severe isoniazid-associated hepatitis--New York, 1991-1993.

  1993cited by this paper
• Hepatitis on high dose isoniazid: reintroduction of the drug in severe tuberculous meningitis.

  1983cited by this paper
• Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.

  1976cited by this paper
• Isoniazid-associated hepatitis.

  1976cited by this paper
• Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.

  1975cited by this paper
• Isoniazid-associated hepatitis. Report of an outbreak.

  1972cited by this paper
• PREVENTIVE TREATMENT IN TUBERCULOSIS: A STATEMENT BY THE COMMITTEE ON THERAPY, AMERICAN THORACIC SOCIETY.

  1965cited by this paper
• Hepatitis following isoniazid.

  1955cited by this paper
• TOXIC HEPATITIS WITH JAUNDICE OCCURRING IN A PATIENT TREATED WITH ISONIAZID: REPORT OF A CASE IN A PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA

  1953cited by this paper
• Toxic hepatitis with jaundice occuring in a patient treated with isoniazid.

  1953cited by this paper

• Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics.

  2025cites this paper
• Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors

  2025cites this paper
• Modifying Hy’s Law and eDISH for the modern idiosyncratic DILI era

  2025cites this paper
• Drug-induced liver injury. Part II: Late complications and hepatotoxicity monitoring

  2025cites this paper
• Diagnosis, prevention and risk-management of drug-induced liver injury due to medications used to treat mycobacterium tuberculosis

  2024cites this paper
• Clinical risk factors for moderate and severe antituberculosis drug-induced liver injury

  2024cites this paper
• Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review

  2024cites this paper
• Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement

  2024cites this paper
• Hepatoprotective potential of Phyllanthus niruri and Andrographis paniculata in isoniazid-rifampicin induced hepatotoxicity in rats.

  2023cites this paper
• Anaphylactic Shock After First-Line Treatment With Antituberculosis Drugs in a Patient With Lupus

  2023cites this paper
• AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

  2022cites this paper
• Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury

  2022cites this paper
• Clinical Prediction of Acetylator Phenotype in Tuberculosis Patients on Medicare using Blood Group

  2022cites this paper
• NAT2 polymorphisms associated with the development of hepatotoxicity after first-line tuberculosis treatment in Mexican patients: from genotype to molecular structure characterization.

  2021cites this paper
• Clinical perspectives of isoniazid-induced liver injury

  2021cites this paper
• Comprehensive analysis and insights gained from long-term experience of the Spanish DILI registry.

  2021cites this paper
• Difficulties in Diagnosing and Treating Disseminated Bacillus Calmette-Guérin (BCG) Infection After Intravesical BCG Therapy in a Patient with Liver Cirrhosis: A Case Report

  2021cites this paper
• Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature

  2021cites this paper
• An experimental evaluation of therapeutic effect of Rosa damascena in hepatotoxicity induced by isoniazid

  2021cites this paper
• QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results

  2020cites this paper
• Drug-Induced Liver Injury (DILI): Current status and future directions for drug development and the post-market setting

  2020cites this paper
• Redox imbalance and oxidative DNA damage during isoniazid treatment: A clinical and translational pharmacokinetic study

  2020cites this paper
• Signatures in drug-induced liver injury.

  2020cites this paper
• Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study

  2020cites this paper
• Role of Cytochrome P450s (CYP) in Isoniazid Bioactivation by

  2019cites this paper
• Drug-Induced Liver Injury

  2019cites this paper
• Therapeutic Effect of Nigella sativa Oil in Hepatotoxicity Induced by Isoniazid in Rats

  2019cites this paper
• EASL Clinical Practice Guidelines: Drug-induced liver injury.

  2019cites this paper
• Genome‐Wide Analysis of DNA Methylation and Antituberculosis Drug‐Induced Liver Injury in the Han Chinese Population

  2019cites this paper
• Isoniazid preventive therapy for tuberculosis occurrence in HIV-positive patients in Lesotho

  2019cites this paper
• Hepatoprotective effect of Carica Papaya and Ficus Bengalensis Latex in Isoniazid as an antituberculosis drug Induced liver injury in Rats

  2019cites this paper
• EASL Clinical Practice Guidelines: Drug-induced liver injury

  2019cites this paper
• Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics

  2018cites this paper
• Drugs and Toxins

  2018cites this paper
• Case Report of Isoniazid-Related Acute Liver Failure Requiring Liver Transplantation

  2018cites this paper
• Dysregulation of Na +-taurocholate co-transporting polypeptide ( NTCP ) plays a vital role in isoniazid-induced HepG 2 cells apoptosis

  2018cites this paper
• Nonacetaminophen Drug-Induced Acute Liver Failure.

  2018cites this paper
• THE EFFECT OF ISONIAZID PREVENTIVE THERAPY ON THE OCCURRENCE OF TUBERCULOSIS IN LESOTHO, SOUTHERN AFRICA

  2018cites this paper
• Drug-Induced Liver Injury in Children

  2018cites this paper
• Dysregulation of BSEP and MRP2 May Play an Important Role in Isoniazid-Induced Liver Injury via the SIRT1/FXR Pathway in Rats and HepG2 Cells.

  2018cites this paper
• ISONIAZID INDUCED LIVER DAMAGE; HEALTHY EFFECTS OF SILYMARIN ON LIVER HISTOPATHOLOGY AGAINST ISONIAZID INDUCED LIVER DAMAGE IN RABBITS

  2018cites this paper
• Drug-Induced Liver Injury

  2018cites this paper
• Prediction of drug‐induced liver injury using keratinocytes

  2017cites this paper
• Structured Literature Review of Hepatic Toxicity Caused by Medicines

  2017cites this paper
• Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area

  2017cites this paper
• Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes

  2017cites this paper
• Tuberculosis of the Liver, Biliary Tract, and Pancreas

  2017cites this paper
• Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease

  2016cites this paper
• Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review

  2016influential citation
• Evaluation of acetylator phenotype of isoniazid among tuberculosis patients in delta state Nigeria: update on management of toxicity -

  2016cites this paper
• PROTECTIVE ROLE OF NIGELLA SATIVA OIL IN ISONIAZID INDUCED HEPATOTOXICITY IN RATS

  2016cites this paper
• Isoniazid metabolism and hepatotoxicity

  2016cites this paper
• Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation

  2016cites this paper
• Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs

  2016cites this paper
• Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature

  2016cites this paper
• Reducing Risk of Severe Liver Injury in Patients Treated With Isoniazid.

  2015cites this paper
• The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond.

  2015cites this paper
• Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors

  2014cites this paper
• Major Article

  year unknowncites this paper